Arcus Biosciences (RCUS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $22.12, -3.07% vs the prior close of $22.82.
- Volume 1.43M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RCUS slides 3.1% to $22.12, a 3-month low. Closed at $22.12, -3.07% vs the prior close of $22.82. Day range $21.60–$22.95, opened at $22.79.
RCUS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RCUS slides 3.1% to $22.12, a 3-month low
- Closed at $22.12, -3.07% vs the prior close of $22.82. Day range $21.60–$22.95, opened at $22.79.
- Volume was 1.43M shares, 1.0x its 50-day average of 1.44M.
- Price is -17.9% vs its 50-day average ($26.94) and -10.9% vs its 200-day average ($24.82).
- 52-week range $16.04–$31.74; today's close sits at 39% of that range, 30.3% below the 52-week high.
Oct 15, 2026 — RCUS rises 1.3% to $22.82
- Closed at $22.82, +1.29% vs the prior close of $22.53. Day range $22.53–$23.28, opened at $22.53.
- Volume was 1.21M shares, 0.8x its 50-day average of 1.44M.
- Price is -15.7% vs its 50-day average ($27.07) and -8.1% vs its 200-day average ($24.82).
- 52-week range $15.38–$31.74; today's close sits at 46% of that range, 28.1% below the 52-week high.
Oct 14, 2026 — RCUS ends flat (+0.1%) to $22.53
- Closed at $22.53, +0.09% vs the prior close of $22.51. Day range $22.36–$23.47, opened at $22.82.
- Volume was 1.21M shares, 0.8x its 50-day average of 1.43M.
- Price is -17.1% vs its 50-day average ($27.16) and -9.3% vs its 200-day average ($24.83).
- 52-week range $15.38–$31.74; today's close sits at 44% of that range, 29.0% below the 52-week high.
Oct 13, 2026 — RCUS slides 7.5% to $22.51, a 3-month low
- Closed at $22.51, -7.52% vs the prior close of $24.34. Day range $22.46–$24.00, opened at $23.87.
- Volume was 1.39M shares, 1.0x its 50-day average of 1.42M.
- Price is -17.5% vs its 50-day average ($27.29) and -9.3% vs its 200-day average ($24.83).
- 52-week range $15.09–$31.74; today's close sits at 45% of that range, 29.1% below the 52-week high.
Oct 12, 2026 — RCUS ends flat (-0.3%) to $24.34
- Closed at $24.34, -0.29% vs the prior close of $24.41. Day range $24.12–$24.73, opened at $24.42.
- Volume was 1.34M shares, 0.9x its 50-day average of 1.42M.
- Price is -11.1% vs its 50-day average ($27.39) and -2.0% vs its 200-day average ($24.83).
- 52-week range $14.26–$31.74; today's close sits at 58% of that range, 23.3% below the 52-week high.
Oct 9, 2026 — RCUS rises 2.4% to $24.41
- Closed at $24.41, +2.43% vs the prior close of $23.83. Day range $23.75–$24.58, opened at $23.89.
- Volume was 795.20K shares, 0.6x its 50-day average of 1.42M — lighter than usual.
- Price is -11.1% vs its 50-day average ($27.47) and -1.7% vs its 200-day average ($24.82).
- 52-week range $14.26–$31.74; today's close sits at 58% of that range, 23.1% below the 52-week high.
Oct 8, 2026 — RCUS dips 2.8% to $23.83, a 3-month low
- Closed at $23.83, -2.81% vs the prior close of $24.52. Day range $22.80–$24.38, opened at $24.29.
- Volume was 1.86M shares, 1.3x its 50-day average of 1.40M.
- Price is -13.5% vs its 50-day average ($27.55) and -4.0% vs its 200-day average ($24.82).
- 52-week range $14.18–$31.74; today's close sits at 55% of that range, 24.9% below the 52-week high.
Oct 7, 2026 — RCUS rises 1.0% to $24.52
- Closed at $24.52, +0.99% vs the prior close of $24.28. Day range $23.90–$24.85, opened at $24.23.
- Volume was 1.60M shares, 1.1x its 50-day average of 1.40M.
- Price is -11.2% vs its 50-day average ($27.60) and -1.2% vs its 200-day average ($24.81).
- 52-week range $13.71–$31.74; today's close sits at 60% of that range, 22.7% below the 52-week high.
Oct 6, 2026 — RCUS dips 1.9% to $24.28
- Closed at $24.28, -1.86% vs the prior close of $24.74. Day range $23.96–$24.96, opened at $24.96.
- Volume was 824.80K shares, 0.6x its 50-day average of 1.41M — lighter than usual.
- Price is -12.2% vs its 50-day average ($27.65) and -2.1% vs its 200-day average ($24.80).
- 52-week range $13.61–$31.74; today's close sits at 59% of that range, 23.5% below the 52-week high.
Oct 5, 2026 — RCUS rises 1.2% to $24.74
- Closed at $24.74, +1.23% vs the prior close of $24.44. Day range $24.10–$24.95, opened at $24.19.
- Volume was 1.39M shares, 1.0x its 50-day average of 1.41M.
- Price is -10.8% vs its 50-day average ($27.72) and -0.2% vs its 200-day average ($24.79).
- 52-week range $13.21–$31.74; today's close sits at 62% of that range, 22.0% below the 52-week high.
Oct 2, 2026 — RCUS slides 3.1% to $24.44
- Closed at $24.44, -3.13% vs the prior close of $25.23. Day range $24.09–$25.58, opened at $25.48.
- Volume was 1.04M shares, 0.7x its 50-day average of 1.41M.
- Price is -12.1% vs its 50-day average ($27.79) and -1.3% vs its 200-day average ($24.77).
- 52-week range $12.90–$31.74; today's close sits at 61% of that range, 23.0% below the 52-week high.
RCUS latest news & SEC filings
Every SEC filing by or about RCUS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form CT ORDER — CT ORDER filing
CT ORDER filing
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Azoy Alexander sold 2,827 shares at $30.00 (≈$84.81K) on Aug 21, 2026
- Azoy Alexander sold 2,827 shares at $30.00 (≈$84.81K) on Aug 21, 2026
- Azoy Alexander sold 2,827 shares at $30.00 (≈$84.81K) on Aug 21, 2026
- Azoy Alexander sold 2,827 shares at $30.00 (≈$84.81K) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 7, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $33.00M (prior year $8.00M) (+312.5% vs Jun 30, 2025)
- Net income: -$91.00M (prior year $0)
- Diluted EPS: -$0.72 (prior year $0.00)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jaen Juan C. sold 268 shares at $29.40 (≈$7.88K) on Jul 10, 2026
- Jaen Juan C. sold 19,799 shares at $28.61 (≈$566.45K) on Jul 10, 2026
- Jaen Juan C. sold 268 shares at $29.40 (≈$7.88K) on Jul 10, 2026
- Jaen Juan C. sold 19,799 shares at $28.61 (≈$566.45K) on Jul 10, 2026
- Jaen Juan C. sold 268 shares at $29.40 (≈$7.88K) on Jul 10, 2026
- Jaen Juan C. sold 19,799 shares at $28.61 (≈$566.45K) on Jul 10, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 24, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jaen Juan C. sold 6,431 shares at $29.66 (≈$190.74K) on Jun 24, 2026
- Jaen Juan C. sold 6,431 shares at $29.66 (≈$190.74K) on Jun 24, 2026
- Jaen Juan C. sold 6,431 shares at $29.66 (≈$190.74K) on Jun 24, 2026
- Jaen Juan C. sold 6,431 shares at $29.66 (≈$190.74K) on Jun 24, 2026
- Jaen Juan C. sold 1,697 shares at $28.06 (≈$47.62K) on Jun 23, 2026
- Jaen Juan C. sold 14,067 shares at $27.69 (≈$389.52K) on Jun 23, 2026
- …plus 3 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade RCUS
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 25, 2026, Oct 28, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.20% (largest 7.5%).
- Liquidity: about 1.36M shares (≈$30.01M) trade per day on average.
- 52-week position: $22.12 vs a range of $16.04–$31.74 (39% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Alexander Azoy sold 2,827 shares on Aug 21, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 12, 2026.
- Share count: 127.33M shares outstanding (Jul 30, 2026), +19.6% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
RCUS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 22.79 | 22.95 | 21.60 | 22.12 | 1.43M |
| Oct 15, 2026 | 22.53 | 23.28 | 22.53 | 22.82 | 1.21M |
| Oct 14, 2026 | 22.82 | 23.47 | 22.36 | 22.53 | 1.21M |
| Oct 13, 2026 | 23.87 | 24.00 | 22.46 | 22.51 | 1.39M |
| Oct 12, 2026 | 24.42 | 24.73 | 24.12 | 24.34 | 1.34M |
| Oct 9, 2026 | 23.89 | 24.58 | 23.75 | 24.41 | 795.20K |
| Oct 8, 2026 | 24.29 | 24.38 | 22.80 | 23.83 | 1.86M |
| Oct 7, 2026 | 24.23 | 24.85 | 23.90 | 24.52 | 1.60M |
| Oct 6, 2026 | 24.96 | 24.96 | 23.96 | 24.28 | 824.80K |
| Oct 5, 2026 | 24.19 | 24.95 | 24.10 | 24.74 | 1.39M |
| Oct 2, 2026 | 25.48 | 25.58 | 24.09 | 24.44 | 1.04M |
| Oct 1, 2026 | 25.86 | 26.26 | 25.13 | 25.23 | 1.36M |
| Sep 30, 2026 | 26.18 | 26.35 | 25.56 | 25.83 | 1.36M |
| Sep 29, 2026 | 24.93 | 26.04 | 24.76 | 25.65 | 1.25M |
| Sep 28, 2026 | 24.85 | 25.50 | 24.35 | 25.01 | 1.25M |
| Sep 25, 2026 | 25.16 | 25.29 | 24.33 | 24.97 | 1.72M |
| Sep 24, 2026 | 26.20 | 26.49 | 24.42 | 25.06 | 2.04M |
| Sep 23, 2026 | 26.86 | 27.90 | 25.84 | 26.39 | 1.56M |
| Sep 22, 2026 | 26.34 | 27.11 | 26.04 | 26.87 | 1.39M |
| Sep 21, 2026 | 25.54 | 26.03 | 25.06 | 25.95 | 1.11M |
About Arcus Biosciences
Arcus Biosciences (RCUS) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HAYWARD, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1724521.
RCUS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kathryn E Falberg | Director | Jun 12, 2026 |
| Yasunori Kaneko | Director | Jun 12, 2026 |
| David L. Lacey | Director | Jun 12, 2026 |
| Nicole Lambert | Director | Jun 12, 2026 |
| Patrick Machado | Director | Jun 12, 2026 |
| Andrew J Perlman | Director | Jun 12, 2026 |
| Terry J Rosen | Chief Executive Officer | Jan 26, 2026 |
| Antoni Ribas | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Alexander Azoy | Chief Accounting Officer | Aug 24, 2026 |
| Ii Robert C. Goeltz | Chief Financial Officer | May 12, 2026 |
| Juan C. Jaen | President | Jul 13, 2026 |
| Jennifer Jarrett | Chief Operating Officer | Jan 26, 2026 |
| Richard Markus | Chief Medical Officer | Jan 26, 2026 |
| Terry J Rosen | Chief Executive Officer | Jan 26, 2026 |
| Carolyn C. Tang | General Counsel | Jun 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | Alexander Azoy | Sale | 2,827 | $30.00 |
| Aug 21, 2026 | Alexander Azoy | Sale | 2,827 | $30.00 |
| Aug 21, 2026 | Alexander Azoy | Sale | 2,827 | $30.00 |
| Aug 21, 2026 | Alexander Azoy | Sale | 2,827 | $30.00 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 268 | $29.40 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 19,799 | $28.61 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 268 | $29.40 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 19,799 | $28.61 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 268 | $29.40 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 19,799 | $28.61 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 268 | $29.40 |
| Jul 10, 2026 | Juan C. Jaen | Sale | 19,799 | $28.61 |
| Jul 9, 2026 | Juan C. Jaen | Sale | 48,502 | $30.05 |
| Jul 9, 2026 | Juan C. Jaen | Sale | 48,502 | $30.05 |
| Jul 9, 2026 | Juan C. Jaen | Sale | 48,502 | $30.05 |
RCUS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $33.00M | $-353.00M | -3.29 | $-482.00M |
| Dec 31, 2024 | $51.00M | $-283.00M | -3.14 | $-170.00M |
| Dec 31, 2023 | $37.00M | $-307.00M | -4.15 | $-306.00M |
| Dec 31, 2022 | $38.00M | $-267.00M | -3.71 | $438.00M |
| Dec 31, 2021 | $383.00M | $53.00M | 0.71 | $-256.00M |
Latest balance sheet: total assets $924.00M, total liabilities $695.12M, cash $150.00M (as of Jun 30, 2026).
RCUS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $27.70 |
| May 5, 2026 | 8-K Item 2.02 (results) | $26.06 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $20.27 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $19.88 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $9.49 |
| May 6, 2025 | 8-K Item 2.02 (results) | $8.12 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $10.24 |
| Feb 18, 2025 | 8-K Item 2.02 (results) | $10.96 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $15.73 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 21, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RCUS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.